Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2012-09-28 Declaration of Voting R…
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Release according to Article 26a, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Total Voting Rights Announcement' and explicitly references Article 26a, Section 1 of the WpHG (German Securities Trading Act). It states the total number of voting rights as of the end of September 2012. This type of announcement, detailing the total number of shares with voting rights, directly corresponds to the definition of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports on the fundamental voting structure of the company, even if it's not the final result of a specific vote, it is a mandatory disclosure related to voting power.
2012-09-28 English
UniCredit & Kepler German Investment Conference
Investor Presentation Classification · 98% confidence The document is titled 'UniCredit & Kepler – German Investment Conference' and contains detailed financial performance data, segment updates (Fresenius Kabi, Helios, Vamed), financial outlooks for 2012, and comparative historical results (Q2/H1 2011 vs Q2/H1 2012). It includes tables for Sales, EBIT, Net Income, and Cash Flow, along with forward-looking statements and dividend information. This structure strongly indicates a presentation given to investors or analysts, likely summarizing recent performance and future guidance. This aligns best with the 'Investor Presentation' (IP) category, which covers detailed presentations focusing on financials and strategy, rather than a formal regulatory filing like 10-K or ER.
2012-09-27 English
Goldman Sachs Berenberg German Corporate Conference
Investor Presentation Classification · 98% confidence The document is titled "Goldman Sachs & Berenberg Bank – German Corporate Conference" and contains detailed financial performance metrics, segment updates (Fresenius Kabi, Helios, Vamed), 2012 financial outlooks, and attached Profit and Loss and Cash Flow statements. The content is highly detailed, covering multiple periods (H1/12, Q2/12 vs Q2/11) and providing forward-looking guidance. This structure is characteristic of an Investor Presentation (IP) or a detailed Management Discussion and Analysis (MDA) often presented at investor conferences. Since it is a presentation format (implied by the conference context and structure) detailing strategy and financials, Investor Presentation (IP) is the most appropriate classification over a standard Earnings Release (ER) or Interim Report (IR), which are typically more formal regulatory filings. The document length is substantial (over 43k characters), ruling out a simple Report Publication Announcement (RPA).
2012-09-26 English
Sanford C. Bernstein Strategic Decisions Conference
Investor Presentation Classification · 98% confidence The document text is titled 'Sanford C. Bernstein – Strategic Decisions Conference' and contains detailed financial performance updates, segment breakdowns (Fresenius Medical Care, Kabi, Helios, Vamed), 2012 financial outlooks, and attached Profit and Loss/Cash Flow statements. The content is highly analytical and forward-looking, typical of a presentation given to investors or analysts at a conference. This format strongly suggests an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or IR, nor is it a brief earnings release (ER).
2012-09-20 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and details transactions made by a person performing managerial responsibilities ("Member of a managing body"). It specifies the name of the person (Dr. Ulf M. Schneider), the type of transaction ("Exercise of stock options against cash settlement"), the date, and the instrument (Fresenius SE & Co. KGaA Ordinary Share). This content directly matches the definition for Director's Dealing reports.
2012-09-17 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and details a transaction made by a 'Member of an administrative or supervisory body' (Gerd Krick) involving the company's ordinary shares, including the date, price, and nature of the transaction (Exercise of stock options). This directly corresponds to the definition of Director's Dealing, which is classified under the code DIRS.
2012-09-13 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.